Investor Relations

Overview

BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. Our wholly owned subsidiary, OnkosXcel Therapeutics, is focused on the development of medicines in immuno-oncology. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. 

 

Events

Latest Annual Filing

Form Filing date Description View
10-K

Annual report which provides a comprehensive overview of the company for the past year

View HTML EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
      Sign Up for Email Alerts
Receive updates straight into your inbox

BioXcel Therapeutics, Inc.


Data Provided by Refinitiv.

Price
Change
Volume
52 Week High
52 Week Low

Contacts

Corporate/Investors

BioXcel Therapeutics
Erik Kopp


Media

Russo Partners
David Schull
T: 858-717-2310
David.schull@russopartnersllc.com